Azole derivatives have been used as antifungal drugs in clinical practice for many years. However, limitations such as drug-drug interactions, severe adverse events from prolonged use, and high resistance prevalence highlight the urgent need for new therapeutic options to treat the rising number of invasive fungal infections.
Researchers at Centre Hospitalier Universitaire de Grenoble Alpes, Centre National de la Recherche Scientifique, Commissariat à l’Energie Atomique, Institut National de la Santé et de la Recherche Médicale, Université Grenoble Alpes and Université Libre de Bruxelles have synthesized calix[4]arene compounds reported to be useful for treatment of cancer, metastatic cancer, and bacterial, viral, fungal and parasitic infections.
Current approved antifungal therapies are limited by their associated adverse events. SCY-247 is a new triterpenoid antifungal for intravenous or oral administration that inhibits the glucan synthase enzyme, which is a key member for the fungal cell wall.
Researchers from Second Military Medical University PLA (Shanghai) and affiliated organizations announced the discovery and preclinical characterization of novel antifungal small-molecule candidates.
Researchers from Scynexis Inc. have recently presented details on the preclinical characterization of SCY-247, a second-generation triterpenoid with glucan synthase inhibitor activity and intended to be used for the treatment of invasive mucormycosis.
At the IDWeek 2023 infectious disease conference held last week in Boston, fungal infections got the audience’s attention during the session titled, “The antifungal evolution: novel strategies for a changing world.” With the emergence of some resistant pathogens such Candida auris and the growing disease burden in the population at risk for life-threatening fungal infections, these pathogens are more than ever standing out within the infectious diseases arena.
Fearing cross contamination might have occurred during manufacturing, Scynexis Inc. is recalling Brexafemme (ibrexafungerp tablets) from the market and putting a temporary hold on the drug’s clinical trials until it knows more details.
